Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study
2011; Springer Science+Business Media; Volume: 30; Issue: 5 Linguagem: Inglês
10.1007/s10637-011-9721-6
ISSN1573-0646
AutoresGerardo Rosati, Stefano Cordio, Giuseppe Aprile, Alfredo Butera, Antonio Avallone, Giuseppe Di Lucca, F. De Pauli, Héctor Soto Parrà, Giorgio Reggiardo, Roberto Bordonaro,
Tópico(s)Hepatocellular Carcinoma Treatment and Prognosis
Referência(s)